Molecular Templates, Inc. (MTEM) Stock

About Molecular Templates, Inc.

Molecular Templates, Inc. (MTEM) is a clinical-stage biopharmaceutical firm dedicated to the identification and progression of biological therapies for oncology and other significant health conditions. The company's core development strategy relies on its unique engineered toxin body (ETB) drug platform to construct a robust pipeline of treatments. Currently, several of its ETB candidates are undergoing Phase I clinical evaluation: MT-5111 is being assessed for HER2-positive cancers; MT-0169 is in trials for individuals with relapsed or refractory myeloma; and MT-6402 targets patients who have not responded to prior PD-1/PD-L1 antibody treatments. Beyond these, Molecular Templates is also developing ETBs to engage other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. Furthermore, the company has forged a collaborative partnership with Bristol Myers Squibb to jointly discover and advance innovative ETB-based products designed for a diverse array of biological targets. Established in 2001, Molecular Templates, Inc. is headquartered in Austin, Texas.

Molecular Templates, Inc. (MTEM) stock trades at $0.00 with a market capitalization of $658. The stock is valued at price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $1.59, and currently trades 100.0% below its 52-week high.

On profitability, Molecular Templates, Inc. generates a return on equity (ROE) of -200.00% (negative, reflecting a net loss), return on capital employed of -57.94%, an operating margin of -17.54%, a net profit margin of -14.04%.

Official website: www.mtem.com